Showing 281 - 300 results of 386 for search '(( 6 14 decrease ) OR ( 10 (((peter OR per) decrease) OR (((nn decrease) OR (mean decrease)))) ))*', query time: 0.17s Refine Results
  1. 281
  2. 282
  3. 283
  4. 284

    Mobile Epifauna Associated To Artificial Substrates In Offshore Qatari Waters by Abdulaziz Aziz, Naeem

    Published 2019
    “…After one year, two replicate plates per 5 m depth interval were retrieved and analyzed for each site. …”
    Get full text
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290

    The Expression of TBC1 Domain Family, Member 4 (TBC1D4) in Skeletal Muscles of Insulin-Resistant Mice in Response to Sulforaphane by Rizk, Nasser M

    Published 2020
    “…Results: SFN-treated DIO mice had significantly lower non-fasting blood glucose levels than vehicle-treated mice (194.16 ± 14.12 vs. 147.44 ± 20.31 mg/dL, vehicle vs. SFN, p value=0.0003). …”
    Get full text
    Get full text
  11. 291
  12. 292

    The effect of acute ophiobolin A treatment on HO-mediated inflammatory processes by Posa, Aniko

    Published 2017
    “…Male Wistar rats were treated with 5% ethanol, 0.01 mg/kg OPA, 0.1 mg/kg OPA and 1.0 mg/kg OPA per os. After 24 h of the administrations, inflammatory mediators such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-) and myeloperoxidase (MPO) enzyme as well as heme oxygenase (HO) activity were measured in both plasma and cardiac tissue, along with serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). …”
    Get full text
    Get full text
  13. 293

    Molecular and Structural Changes in Induced-Brain Stroke Tissue Using FTIR Imaging Spectroscopy, Scanning Electron and Atomic Force Microscopy by Ali, Mohamed H

    Published 2016
    “…In Qatar, stroke is a major health problem with an estimated incidence of 238/100,000 per year for the population over 45 years old [1]. …”
    Get full text
    Get full text
  14. 294
  15. 295
  16. 296
  17. 297
  18. 298

    The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target? by Al-Shamasi, Al-Anood

    Published 2020
    “…In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). …”
    Get full text
    Get full text
  19. 299
  20. 300

    Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: A cross-sectional study in the State of Qatar by El Hajj, Maguy Saffouh

    Published 2016
    “…More than 70% responded with rarely or never to 6 out of the 10 CVD health promotion activities. Eighty-four per cent and 68% always or often describe to patients the appropriate time to take antihypertensive medications and the common medication adverse effects, respectively. …”
    Get full text
    Get full text